

AD _____

Award Number: W81XWH-05-1-0205

TITLE: Modeling Phenotypes of Tuberous Scerosis in the Mouse

PRINCIPAL INVESTIGATOR: James Michael Shipley, Ph.D.

CONTRACTING ORGANIZATION: Washington University
St Louis MO 63130-4899

REPORT DATE: February 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-02-2007		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 10 Jan 2006 – 09 Jan 2007	
4. TITLE AND SUBTITLE Modeling Phenotypes of Tuberous Scerosis in the Mouse				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-05-1-0205	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) James Michael Shipley, Ph.D. E-Mail: mshipley@im.wustl.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Washington University St Louis MO 63130-4899				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The overall goal of this project is to generate a mouse model of the smooth muscle-related facets of tuberous sclerosis, specifically in an attempt to model the lung phenotype seen in a subset of TS patients and patients with LAM. We have conditionally targeted the TSC1 gene in smooth muscle, which results in mortality at approximately 10 weeks of age. This mouse now provides a useful model in which to investigate the function of individual MMPs or other proteins in this pathological progression, and to evaluate relevant therapeutic interventions such as rapamycin.					
15. SUBJECT TERMS MOUSE MODEL, MMP, CONDITIONAL TARGETING, INDUCIBLE EXPRESSION, TSC1					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	8	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Page

Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusion.....	8
References.....	8
Appendices.....	8

Introduction

The overall goal of the project is to generate a mouse model in which one of the two tumor suppressor genes responsible for tuberous sclerosis, TSC1 or TSC2, are dysregulated specifically in smooth muscle. This was to be accomplished in one of two ways, including (1) specifically targeting the TSC1 gene in smooth muscle using a doxycycline-inducible transgenic system which we adapted for expression of cre recombinase in smooth muscle, or (2) by overexpression of a potentially dominant negative form of tuberin in smooth muscle. Should either of these approaches work, the goal was then to evaluate whether matrix metalloproteinase (MMP) expression was dysregulated in the mouse model or in TSC1 $-/-$ cells derived from these mice, whether rapamycin treatment corrects this dysregulation in cultured cells, and whether phenotypes seen in the mice are abrogated by breeding pertinent MMP knockout alleles into the model.

Body

In the approved statement of work, individual specific aims were broken down into tasks, and these individual tasks were planned over the two year duration of the award. In the **first specific aim** (targeting the TSC1 gene in smooth muscle using conditional cre mice we have generated and evaluate resulting phenotypes), we needed to generate mice which harbor 4 separate components including two floxed alleles of the TSC1 gene, one SMP8-rtTA transgene, and the tetO-cre transgene. We maximized the chances of discovering a phenotype by beginning doxycycline administration as early as possible, by giving it continuously both to pregnant female mice and to their offspring upon weaning. We found that inactivation of TSC1 in this context causes mortality in these mice at an average age of 10 weeks. Alveolar ducts in the lungs of these mice are enlarged relative to controls (mice on doxycycline but lacking the rtta or cre transgenes)(Figure 1), and in some cases (~30%) we see nodules similar to those seen in human TS and LAM (Figure 2). Immunostaining reveals loss of TSC1 protein in cells in which active cre recombinase is expressed (Figure 3), as these cells are marked by recombination of a ROSA allele that results in β -galactosidase activity following cre-mediated recombination (blue). Another well-characterized readout for dysregulation of the TSC1/TSC2 pathway is activation of ribosomal protein S6 (phosphorylation), which is normally negatively regulated by the tuberin/hamartin complex. Total lung extracts from control mice show minimal phosphorylation of ribosomal protein S6(Figure 4, lanes 1-4), which is markedly induced in the lungs of our smooth muscle-specific TSC1 knockout mice (lanes 5-8). One hypothesis in TS/LAM is that lung destruction is mediated by metalloproteinases, particularly MMP-2 and -9, which is upregulated (MMP-9) in the lungs of these patients relative to controls (Figure 5). Indeed, we observe increased MMP-9 activity in the lungs of the smooth muscle-specific TSC1 knockouts relative to controls (Figure 6). Taken together, many of the pulmonary facets of human TS/LAM are recapitulated in the lungs of the smooth muscle-specific TSC1 knockout mice.




Figure 1. Morphology of TSC1 Conditional Knockout Lungs. Shown are lungs from a TSC1 conditional knockout (right) and a control littermate (left) sacrificed at 9 weeks, demonstrating enlarged airspaces in the knockout.




Figure 2. Ki-67 Immunostaining on TSC1 Conditional Knockout Lungs. Lungs were stained for Ki-67, a marker of proliferating cells. Areas that appear nodular show many Ki-67-positive cells.




Figure 3. TSC1 immunostaining in the conditional TSC1 knockout. The ROSA26 reporter allele for cre activity was bred onto the conditional knockout background, and lung sections were stained for either β -galactosidase activity with X-Gal (left, marks cre-positive cells) or for an antibody to TSC1 (right). Note the smooth muscle expressing cre which is negative for TSC1, in contrast to the surrounding tissue (arrows).




Figure 4. Activation of ribosomal protein S6 phosphorylation in TSC1 conditional knockout mice. Total lung extracts from control mice (lanes 1-4) or TSC1 conditional knockout mice (lanes 5-8) were evaluated for phosphorylation (activation) of ribosomal protein S6 by western blotting, demonstrating activation of this pathway in TSC1 conditional knockout mice.




Figure 5. Expression of MMPs -2 and -9 in LAM. Ten microliters of BAL from each of three LAM patients was analyzed by gelatin zymography. Expression of MMP-9/gelatinase B (top arrow) and MMP-2/gelatinase A (bottom arrow) is seen. These proteases are undetectable in the BAL of control subjects (not shown). Increased expression of MMP-2 and MMP-9 corroborates gene expression profiling data by others on LAM tissue which shows these MMPs induced in LAM relative to biopsy specimens from control subjects.





Figure 6. Increased MMP-9 activity in Conditional TSC1 knockout lungs. The caudal lobe of the right lung of two controls (lanes 1 and 2) and one conditional TSC1 knockout (lane 3) were used for gelatin zymography. Increased MMP-9 activity is seen in the the total lung extract of the conditional TSC1 knockout animal.

The goals of the **second specific aim** were very similar to those of the first aim, but in this case the approach was to overexpress a potentially dominant negative form of the TSC2 gene product, tuberin, in smooth muscle cells in mice with the goal being to inactivate TSC function. While we were able to achieve significant overexpression of this form of tuberin in these mice upon induction by doxycycline (Figure 7), this approach did not yield a phenotype, at least after 6 months of doxycycline treatment. Thus, as our overall hope was for one of these two models to prove fruitful, and the conditional TSC1 knockout (specific aim 1) has proven to yield a highly penetrant phenotype, we have focused our attention on the analysis of the phenotype in this model.



One of the goals of **specific aim 3** was to establish cultures of smooth muscle cells or lung fibroblasts from the mice to evaluate rapamycin as a treatment in culture for any aberrations that we might identify (altered S6K phosphorylation, increased MMP production). At the time of grant submission, we felt that it was unlikely that this would be possible within the two year time frame of the grant. Efforts to establish these primary cell cultures have been difficult but are ongoing. However, we are extending the scope of these studies *in vivo* by treating mice with rapamycin and evaluating the effects on phenotypes which we have observed (life expectancy, airspace enlargement, MMP production, pulmonary nodule formation, S6K phosphorylation in the lung). Within the last week, we finalized an agreement with Wyeth Pharmaceuticals to supply us with enough rapamycin to do these experiments.

Rapamycin has been shown to be effective in mice at a dose of 1.5-4 mg/kg/day when delivered intraperitoneally. We will therefore use 3 mg/kg/day as the starting point for these experiments. Based on similar studies by other groups, we will administer rapamycin 3 times per week beginning at 4 weeks of age and continuing for the remainder of the life of the animal. This would be a dose of 75 micrograms / 25 gram mouse/day, or 225 micrograms rapamycin/week/mouse. For each rapamycin treatment arm (4 total described below), we anticipate cohorts of 10 mice each.

Two doxycycline administration protocols (for induction of cre recombinase) will be used. In the first, we will administer doxycycline as we have thus far beginning at conception and throughout the life of the animal. In this setting, we recognize that we will be allowing the disease progress throughout the prenatal period and until 4 weeks postnatal when rapamycin administration will begin, which may not be an optimal strategy for defining whether rapamycin treatment can prevent the disease in these mice. However, we have established the phenotypic parameters using this doxycycline administration paradigm, and thus can immediately evaluate any positive effects of rapamycin in this setting. As mentioned above, the TSC1 conditional knockout mice die at approximately 10 weeks of age using this approach, with induction of MMP-9 and pulmonary nodule formation (albeit not in all animals), in the absence of any intervention.

The second approach will be to re-establish the time course of phenotype onset when doxycycline is not administered until 4 weeks of age. This will do two things. First, it will allow us to determine whether effects on airspace enlargement are developmental vs. destructive in nature, as formation of lung alveoli is not complete until 4 weeks of age in mice. Secondly, and importantly for these studies, it will allow us to evaluate the impact of rapamycin beginning when the phenotypic changes are initiated. We will therefore redefine the time course of the phenotypic parameters mentioned above using this doxycycline protocol. Time points for analysis with rapamycin will be determined based on these findings. Using both methods of doxycycline protocols, we would anticipate at least 2 cohorts of mice: (1) those in which we monitor survival, and (2) a second which are sacrificed at 80-90% of their lifespan for analysis of airspace enlargement, proliferation in the lung, and MMP production.

Based on these findings, if rapamycin is able to abrogate development of disease in these mice, we anticipate future experiments (not planned here) where we would evaluate whether rapamycin can reverse the course of the disease after significant phenotypic changes are allowed to first occur. In this case, we would anticipate administering rapamycin at 8 weeks of age, two weeks before the mice will otherwise die, and a time at which significant airspace enlargement is seen.

For the experiments in mice involving rapamycin, we believe it would be beneficial to increase the yield of mice which contain all 4 necessary alleles. To this end, we are in the process of modifying our breeding strategy. The goal of the new strategy will be to generate mice which are either homozygous for both the rtTA transgene and the floxed TSC1 allele, and mice which are homozygous for the cre transgene and the floxed TSC1 allele. Upon breeding mice of these genotypes, all of the offspring would contain the 4 necessary transgenes, thereby markedly increasing the efficiency of the process. Unfortunately, we have no genotyping assay that will discriminate between mice which are heterozygous vs. homozygous for the rtTA or cre transgenes. Ultimately, this test will be strictly empirically determined, ie., we will only know that a parent is homozygous for either the rtTA or cre transgenes when all of its offspring are positive for the transgene. We are currently evaluating candidates by a combination of quantitative southern blotting and real time PCR of genomic DNA for the rtTA and cre transgenes. We hope to have candidate mice within the next month that will allow us to set up these new breeding pairs in which all the offspring will carry each transgene/allele.

Finally, we outlined in the statement of work that should MMP induction (or repression) be seen in the TSC1 conditional knockout mice, we would attempt to breed the relevant MMP knockout allele into the model in order to evaluate the contribution of the particular MMP to the pathologic progression. Indeed, MMP-9 and -12 have been implicated as contributing to the airspace enlargement seen in human COPD, as well as in animal models of pulmonary emphysema. As we have detected increased MMP-9 expression in the TSC1 conditional knockout (both in TSC1 $-/-$ embryonic fibroblasts as well as in the lungs of the adult mice), it will be interesting to determine whether the lifespan or the degree of airspace enlargement is altered in the absence of MMP-9. To this end, we have bred the MMP-9 knockout (which we generated several years ago) into the conditional TSC1 model. The end product will be a mouse with 6 “alleles” (rtTA and cre transgenes, 2 floxed TSC1 alleles, and 2 MMP-9 null alleles), which will be very cumbersome and time consuming to generate. This has been a process that required several steps of breeding, which has been ongoing over the past year, and we are anticipating having conditional TSC1/MMP-9 knockout mice to begin analyzing within the next 1-2 months, albeit at low efficiency (considering the 6 alleles that must be present).

Key Research Accomplishments

- Generation of a mouse model in which conditional targeting of the TSC1 gene in smooth muscle cells results in a reproducible phenotype (mortality at approximately 10 weeks of age).
- Alveolar duct enlargement in the lungs of these mice is a consistent finding.
- Formation of nodules in the lung of these mice is also a reproducible finding, although not as penetrant a phenotype as the mortality and the airspace enlargement.
- MMP-9 induction in the lungs of these mice may contribute to the airspace enlargement (preliminary, gelatin zymography has been conducted on two conditional knockouts vs. two controls).
- Material Transfer Agreement with Wyeth Pharmaceuticals to receive enough rapamycin to conduct a clinical trial in the mice (evaluating the effect of rapamycin on mortality, airspace enlargement, pulmonary

nodule production, and MMP production), which was thought of as a future direction at the time of grant submission

- Breeding of the MMP-9 knockout allele into the TSC1 conditional (TSC1 flox/flox, SMP8-rtTA, tetO-cre) background, an inefficient process requiring multiple breeding steps

Reportable Outcomes

The primary reportable outcome is the success of the conditional TSC1 knockout mouse (described above). These data will form the basis for future grant applications. Also, an abstract on this work was submitted and accepted for presentation at the American Thoracic Society international meeting to be held this May. The abstract is shown below:

Conditional Targeting of the TSC1 gene in Smooth Muscle as a Model of LAM

Yifu Fang*, David J. Kwiatkowski#, and J. Michael Shipley*

*Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO, 63110 and # Hematology Division, Brigham & Women's Hospital, Boston, MA 02115

Dysregulated proliferation of smooth muscle cells is a hallmark of LAM, which involves mutation of either the TSC1 (hamartin) or TSC2 (tuberin) tumor suppressor gene. TSC1 and TSC2 knockout mice die mid gestation, precluding analysis of their lungs as a model of LAM. To circumvent this issue, we developed transgenic mice for doxycycline-inducible expression of cre recombinase in smooth muscle and have used these to conditionally target the TSC1 gene. By RT-PCR, mice which express the reverse tetracycline transcriptional activator (rtTA) under the control of the smooth muscle alpha actin (SMA) promoter show significant rtTA expression in smooth muscle-containing tissues including the lung. These mice were bred to tetO-cre mice and ROSA26 reporter mice to assess doxycycline-inducible expression of active cre recombinase in the lung. Expression was seen in vascular smooth muscle, airway smooth muscle, and myofibroblasts. Bitransgenic SMA-rtTA/tetO-cre mice were bred to “floxed” TSC1 mice where targeting of the TSC1 gene was initiated by administration of doxycycline to the drinking water. Pregnant mothers were given doxycycline water continuously from conception to birth, and the offspring continued to receive doxycycline water throughout their lifespan. TSC1 flox/flox mice containing both the SMA-rtTA and tetO-cre transgenes that received continuous doxycycline had a mean life span of 10 weeks (n=9). Hyperphosphorylation of ribosomal protein S6 kinase is seen in lung extracts, consistent with inactivation of hamartin function. Preliminary evidence suggests abnormal smooth muscle proliferation and airspace enlargement in the lungs of these mice, two facets characteristic of human LAM. Thus, these mice appear to recapitulate important facets of the disease and will be useful in evaluating therapeutic interventions.

Conclusion

These studies should provide a viable model in which to study facets of tuberous sclerosis involving loss of function of TSC1 in smooth muscle, most notably the lung pathology which is also seen in lymphangioleiomyomatosis (LAM). The mice now provide a very useful tool in which to investigate the function of individual MMPs or other proteins in this pathological progression, and to evaluate relevant therapeutic interventions such as rapamycin.

References

N/A

Appendices

None